Q32 Bio Statistics

Total Valuation

Q32 Bio has a market cap or net worth of $304.20 million. The enterprise value is $221.20 million.

Market Cap	304.20M
Enterprise Value	221.20M

Important Dates

The next estimated earnings date is Tuesday, May 7, 2024, before market open.

Earnings Date	May 7, 2024
Ex-Dividend Date	n/a

Share Statistics

Q32 Bio has 11.93 million shares outstanding. The number of shares has increased by 0.76% in one year.

Shares Outstanding	11.93M
Shares Change (YoY)	+0.76%
Shares Change (QoQ)	+0.21%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	261.71
Forward PS	296.60
PB Ratio	4.14
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	191.35
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.25, with a Debt / Equity ratio of 0.02.

Current Ratio	7.25
Quick Ratio	n/a
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -104.50% and return on invested capital (ROIC) is -136.50%.

Return on Equity (ROE)	-104.50%
Return on Assets (ROA)	-76.30%
Return on Capital (ROIC)	-136.50%
Revenue Per Employee	$31,243
Profits Per Employee	-$3.05M
Employee Count	37
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +41.36% in the last 52 weeks.

Beta (1Y)	n/a
52-Week Price Change	+41.36%
50-Day Moving Average	18.21
200-Day Moving Average	16.88
Relative Strength Index (RSI)	62.59
Average Volume (30 Days)	33,699

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Q32 Bio had revenue of $1.16 million and -$112.96 million in losses. Loss per share was -$35.10.

Revenue	1.16M
Gross Profit	1.16M
Operating Income	-101.43M
Pretax Income	-112.96M
Net Income	-112.96M
EBITDA	-110.32M
EBIT	-112.96M
Loss Per Share	-$35.10

Full Income Statement

Balance Sheet

The company has $82.65 million in cash and $1.32 million in debt, giving a net cash position of $81.34 million or $6.82 per share.

Cash & Cash Equivalents	82.65M
Total Debt	1.32M
Net Cash	81.34M
Net Cash Per Share	$6.82
Equity / Book Value	72.99M
Book Value Per Share	6.12
Working Capital	72.34M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$96.23 million and capital expenditures $326,000, giving a free cash flow of -$95.90 million.

Operating Cash Flow	-96.23M
Capital Expenditures	326,000
Free Cash Flow	-95.90M
FCF Per Share	-$29.85

Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -8,774.13% and -9,771.71%.

Gross Margin	100.00%
Operating Margin	-8,774.13%
Pretax Margin	-9,771.71%
Profit Margin	-9,771.71%
EBITDA Margin	-9,543.08%
EBIT Margin	-9,771.71%
FCF Margin	-8,296.19%

Dividends & Yields

Q32 Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.76%
Shareholder Yield	-0.76%
Earnings Yield	-37.34%
FCF Yield	-31.70%

Analyst Forecast

The average price target for Q32 Bio is $47.50, which is 86.28% higher than the current price. The consensus rating is "Buy".

Price Target	$47.50
Price Target Difference	86.28%
Analyst Consensus	Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Q32 Bio has an Altman Z-Score of 3.34 and a Piotroski F-Score of 1.

Altman Z-Score	3.34
Piotroski F-Score	1